Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

The ErbB family (HER-1, HER-2, HER-3 and HER-4) of receptor tyrosine kinases has been the focus of cancer immunotherapeutic strategies while antiangiogenic therapies have focused on VEGF and its receptors VEGFR-1 and VEGFR-2. Agents targeting receptor tyrosine kinases in oncology include therapeutic antibodies to receptor tyrosine kinase ligands or the receptors themselves, and small-molecule inhibitors. Many of the US FDA-approved therapies targeting HER-2 and VEGF exhibit unacceptable toxicities, and show problems of efficacy, development of resistance and unacceptable safety profiles that continue to hamper their clinical progress. The combination of different peptide vaccines and peptidomimetics targeting specific molecular pathways that are dysregulated in tumors may potentiate anticancer immune responses, bypass immune tolerance and circumvent resistance mechanisms. The focus of this review is to discuss efforts in our laboratory spanning two decades of rationally developing peptide vaccines and therapeutics for breast cancer. This review highlights the prospective benefit of a new, untapped category of therapies biologically targeted to EGF receptor (HER-1), HER-2 and VEGF with potential peptide 'blockbusters' that could lay the foundation of a new paradigm in cancer immunotherapy by creating clinical breakthroughs for safe and efficacious cancer cures.

[1]  A. Sckell,et al.  Targeting HER‐2/neu for active‐specific immunotherapy in a mouse model of spontaneous breast cancer , 1999, International journal of cancer.

[2]  G. Pawelec,et al.  HER-2/neu-derived peptide 884–899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones , 2001, Cancer Immunology, Immunotherapy.

[3]  J. Melamed,et al.  EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance , 2008, Molecular Cancer Therapeutics.

[4]  Molly Brewer,et al.  Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Mizejewski.  Peptides as receptor ligand drugs and their relationship to G-coupled signal transduction , 2001, Expert opinion on investigational drugs.

[6]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[7]  Y. Yarden,et al.  Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2 , 1995, Molecular and cellular biology.

[8]  T. Bozanovic,et al.  Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer , 2012, Oncoimmunology.

[9]  W. Schmiegel,et al.  Drug Insight: antiangiogenic therapies for gastrointestinal cancers—focus on monoclonal antibodies , 2008, Nature Clinical Practice Gastroenterology &Hepatology.

[10]  E. Mittendorf,et al.  The GP2 peptide: A HER2/neu‐based breast cancer vaccine , 2012, Journal of surgical oncology.

[11]  Brian Higgins,et al.  Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.

[12]  M. Dewhirst,et al.  Synergy between tumor immunotherapy and antiangiogenic therapy. , 2003, Blood.

[13]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  William Pao,et al.  Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase , 2011, Proceedings of the National Academy of Sciences.

[15]  J. Feliu,et al.  Cardiac toxicity: old and new issues in anti-cancer drugs , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[16]  B. Keyt,et al.  The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. , 1997, Structure.

[17]  Markus Klinger,et al.  Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu1 , 2004, The Journal of Immunology.

[18]  R. Nahta.  Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. , 2012, Current medicinal chemistry.

[19]  Michael C. Ostrowski,et al.  An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. , 2010, Cancer research.

[20]  J. Murray,et al.  Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. Winer,et al.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. , 1991, Molecular endocrinology.

[22]  J. Folkman,et al.  Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin , 2006, Science's STKE.

[23]  H. Dvorak,et al.  VEGF-A and the induction of pathological angiogenesis. , 2007, Annual review of pathology.

[24]  Masakazu Toi,et al.  Angiogenic inhibitors: a new therapeutic strategy in oncology , 2005, Nature Clinical Practice Oncology.

[25]  Mirela Anghelina,et al.  Monocytes/macrophages cooperate with progenitor cells during neovascularization and tissue repair: conversion of cell columns into fibrovascular bundles. , 2006, The American journal of pathology.

[26]  L. Vinter‐Jensen.  Pharmacological effects of epidermal growth factor (EGF) with focus on the urinary and gastrointestinal tracts , 1999, APMIS. Supplementum.

[27]  N. Nelson.  Angiogenesis research is on fast forward. , 1999, Journal of the National Cancer Institute.

[28]  H. Pehamberger,et al.  Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her‐2/neu , 2003, International journal of cancer.

[29]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Korc,et al.  Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. , 1995, Cancer research.

[31]  D. Mulvey,et al.  Three dimensional structure of the transmembrane region of the proto‐oncogenic and oncogenic forms of the neu protein. , 1992, The EMBO journal.

[32]  D Eisenberg,et al.  Identification of a Heregulin Binding Site in HER3 Extracellular Domain* , 2001, The Journal of Biological Chemistry.

[33]  C. Peschle,et al.  Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. , 2003, Blood.

[34]  A. Berezov,et al.  HER2/Neu: mechanisms of dimerization/oligomerization , 2002, Oncogene.

[35]  M. Cheever,et al.  Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  A. Amici,et al.  Genetic immunization against neu /erbB2 transgenic breast cancer , 1998, Cancer Immunology, Immunotherapy.

[37]  G. Mcmahon,et al.  VEGF receptor signaling in tumor angiogenesis. , 2000, The oncologist.

[38]  B. Seliger,et al.  CD4+ T cell‐mediated HER‐2/neu‐specific tumor rejection in the absence of B cells , 2004, International journal of cancer.

[39]  M. Slomiany,et al.  IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. , 2006, Biochemical and biophysical research communications.

[40]  W. Gullick,et al.  Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3. , 2001, Cellular signalling.

[41]  A. Bikfalvi,et al.  Structure and Inhibitory Effects on Angiogenesis and Tumor Development of a New Vascular Endothelial Growth Inhibitor* , 2003, Journal of Biological Chemistry.

[42]  G. Stamp,et al.  EXPRESSION OF THE TYPE 1 TYROSINE KINASE GROWTH FACTOR RECEPTORS EGF RECEPTOR, c‐erbB2 AND c‐erbB3 IN BLADDER CANCER , 1996, The Journal of pathology.

[43]  E. Appella,et al.  Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. , 2000, Cancer research.

[44]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Peptide Vaccines for Cancer , 2002, Cancer investigation.

[46]  O. Tsitsilonis,et al.  Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor , 2000, Journal of Immunology.

[47]  P. Davis,et al.  Exploiting the differential production of angiogenic factors within the tumor microenvironment in the design of a novel vascular-targeted gene therapy-based approach to the treatment of cancer. , 2002, International journal of radiation oncology, biology, physics.

[48]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[49]  J. Sheridan,et al.  Peptide vaccines incorporating a ‘promiscuous’ T‐cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity , 1993, Journal of molecular recognition : JMR.

[50]  S. Tsujitani,et al.  Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. , 1998, British Journal of Cancer.

[51]  Matthew L. Freedman,et al.  Analysis of the 10q11 Cancer Risk Locus Implicates MSMB and NCOA4 in Human Prostate Tumorigenesis , 2010, PLoS genetics.

[52]  W. Carson,et al.  Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo , 2012, Oncoimmunology.

[53]  D. Metzger,et al.  Increased Protection against Pneumococcal Disease by Mucosal Administration of Conjugate Vaccine plus Interleukin-12 , 2003, Infection and Immunity.

[54]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[55]  M. Morrow,et al.  Chemoprevention of breast cancer: a model for change. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  P. Triozzi,et al.  Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. , 2000, Cancer research.

[57]  E. Leung,et al.  Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression , 2001, Cancer Gene Therapy.

[58]  M. Sliwkowski,et al.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.

[59]  G. Mills,et al.  Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.

[60]  Napoleone Ferrara,et al.  VEGF as a Therapeutic Target in Cancer , 2005, Oncology.

[61]  M. Ultsch,et al.  Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab* , 2006, Journal of Biological Chemistry.

[62]  Zhen-ping Zhu,et al.  Inhibition of Tumor Growth and Metastasis by Targeting Tumor-Associated Angiogenesis with Antagonists to the Receptors of Vascular Endothelial Growth Factor , 2004, Investigational New Drugs.

[63]  G. Forni,et al.  Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu1 , 2007, The Journal of Immunology.

[64]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[65]  Na Zhang,et al.  Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells , 2006, Clinical Cancer Research.

[66]  A. D. de Vos,et al.  Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[67]  V. Apostolopoulos,et al.  Rational Peptide-based vaccine design for cancer immunotherapeutic applications. , 2005, Current medicinal chemistry.

[68]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[69]  A. D. de Vos,et al.  VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. , 1998, Structure.

[70]  Jerry M Maniate,et al.  Targeting the EGFR pathway for cancer therapy. , 2006, Current medicinal chemistry.

[71]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[72]  T. Singleton,et al.  Stability of HER-2/neu expression over time and at multiple metastatic sites. , 1993, Journal of the National Cancer Institute.

[73]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[74]  D. Leroith,et al.  The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. , 2005, Cytokine & growth factor reviews.

[75]  M. Hung,et al.  The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells , 2004, Cancer Research.

[76]  M. D. Fletcher,et al.  Partially Modified Retro-Inverso Peptides: Development, Synthesis, and Conformational Behavior. , 1998, Chemical reviews.

[77]  B. Karlan,et al.  Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  L. Anderson,et al.  The ERBB3 receptor in cancer and cancer gene therapy , 2008, Cancer Gene Therapy.

[79]  S. Swain,et al.  A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. , 2006, Clinical breast cancer.

[80]  C. Croce,et al.  microRNA-205 regulates HER3 in human breast cancer. , 2009, Cancer research.

[81]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[83]  N. Valiante,et al.  Recent advances in the discovery and delivery of vaccine adjuvants , 2003, Nature Reviews Drug Discovery.

[84]  N. Moldovan,et al.  Role of monocytes and macrophages in angiogenesis. , 2005, EXS.

[85]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[86]  L. Hennighausen.  Mouse models for breast cancer , 2000, Oncogene.

[87]  A. Levitzki,et al.  Tyrphostins--potential antiproliferative agents and novel molecular tools. , 1990, Biochemical pharmacology.

[88]  P. Kaumaya,et al.  Engineered topographic determinants with alpha beta, beta alpha beta, and beta alpha beta alpha topologies show high affinity binding to native protein antigen (lactate dehydrogenase-C4). , 1993, The Journal of biological chemistry.

[89]  P. Beuzeboc,et al.  Targeting HER2 in other tumor types. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[90]  W. Banks,et al.  Retro-inverso prosaptide peptides retain bioactivity, are stable In vivo, and are blood-brain barrier permeable. , 2000, The Journal of pharmacology and experimental therapeutics.

[91]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[92]  E. Raymond,et al.  Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST) , 2007, Therapeutics and clinical risk management.

[93]  J. Kim,et al.  The Role of ErbB2 Signaling in the Onset of Terminal Differentiation of Oligodendrocytes In Vivo , 2003, The Journal of Neuroscience.

[94]  S. Mader,et al.  Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis , 2000, Oncogene.

[95]  C. Arteaga,et al.  HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. , 2002, Seminars in oncology.

[96]  P. Kaumaya.  Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure? , 2011, Future oncology.

[97]  D. Stern.  ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[98]  R. Lupu,et al.  Herceptin: From the Bench to the Clinic , 2001, Cancer investigation.

[99]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[100]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[101]  N. Moldovan.  Functional adaptation: the key to plasticity of cardiovascular "stem" cells? , 2005, Stem cells and development.

[102]  Hong Liu,et al.  Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. , 2007, International journal of oncology.

[103]  G. Forni,et al.  Peptide Vaccines of the HER-2/neu Dimerization Loop Are Effective in Inhibiting Mammary Tumor Growth In Vivo1 , 2007, The Journal of Immunology.

[104]  S. Jewell,et al.  Suppression of Experimental Autoimmune Encephalomyelitis Using Peptide Mimics of CD281 , 2002, The Journal of Immunology.

[105]  M. Sliwkowski,et al.  A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. , 2011, Cancer cell.

[106]  R. D'Amato,et al.  Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[107]  N. Hynes,et al.  Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling , 1995, Molecular and cellular biology.

[108]  S. Markovic,et al.  Challenges in the development of effective peptide vaccines for cancer. , 2002, Mayo Clinic proceedings.

[109]  J. Baselga,et al.  A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2011, Clinical Cancer Research.

[110]  N. Moldovan,et al.  Monocytes and macrophages form branched cell columns in matrigel: implications for a role in neovascularization. , 2004, Stem cells and development.

[111]  B. Keyt,et al.  Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors , 1996, The Journal of Biological Chemistry.

[112]  A. Renehan,et al.  Response: More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF- Binding Protein-3 , 1999 .

[113]  E. Mittendorf,et al.  AE37: a novel T-cell-eliciting vaccine for breast cancer , 2011, Expert opinion on biological therapy.

[114]  C. Whitacre,et al.  Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. , 2005, The journal of peptide research : official journal of the American Peptide Society.

[115]  A. Stojadinovic,et al.  Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients , 2012, Cancer.

[116]  N. Dakappagari,et al.  Conformational HER-2/neu B-cell Epitope Peptide Vaccine Designed to Incorporate Two Native Disulfide Bonds Enhances Tumor Cell Binding and Antitumor Activities* , 2005, Journal of Biological Chemistry.

[117]  A. Grothey.  Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. , 2006, Oncology.

[118]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[119]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[120]  D. Hanahan,et al.  Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. , 1999, Cancer research.

[121]  S. Ménard,et al.  High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Rosario Perona,et al.  Cell signalling: growth factors and tyrosine kinase receptors , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[123]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[124]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[125]  J. Patard,et al.  Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. , 2008, European urology.

[126]  Werner Scheuer,et al.  Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. , 2009, Cancer research.

[127]  J. Mendelsohn.  Targeting the epidermal growth factor receptor for cancer therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  Bart Landuyt,et al.  Vascular Endothelial Growth Factor and Angiogenesis , 2004, Pharmacological Reviews.

[129]  Piero Musiani,et al.  Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice , 2001, The Journal of experimental medicine.

[130]  R. Jain,et al.  Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[131]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[132]  J. Koch,et al.  Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design1 , 2001, The Journal of Immunology.

[133]  E. Jaffee,et al.  HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. , 2000, Cancer research.

[134]  N. Sergina,et al.  The HER family and cancer: emerging molecular mechanisms and therapeutic targets. , 2007, Trends in molecular medicine.

[135]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[136]  P. Kaumaya,et al.  Combination Treatment with HER-2 and VEGF Peptide Mimics Induces Potent Anti-tumor and Anti-angiogenic Responses in Vitro and in Vivo* , 2011, The Journal of Biological Chemistry.

[137]  N. Ferrara.  The role of VEGF in the regulation of physiological and pathological angiogenesis. , 2005, EXS.

[138]  The Role of the HER-2/neu Oncogene in Gynecologic Cancers , 1996, Journal of the Society for Gynecologic Investigation.

[139]  Wei Chen,et al.  Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.

[140]  R. Kerbel,et al.  Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[141]  Sybill Patan,et al.  Vasculogenesis and Angiogenesis as Mechanisms of Vascular Network Formation, Growth and Remodeling , 2000, Journal of Neuro-Oncology.

[142]  M. Srinivasan,et al.  A Retro-Inverso Peptide Mimic of CD28 Encompassing the MYPPPY Motif Adopts a Polyproline Type II Helix and Inhibits Encephalitogenic T Cells In Vitro1 , 2001, The Journal of Immunology.

[143]  M. Chorev,et al.  Recent developments in retro peptides and proteins--an ongoing topochemical exploration. , 1995, Trends in biotechnology.

[144]  D. Vanrompay,et al.  Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. , 2006, Veterinary research.

[145]  P. Fischer,et al.  The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. , 2003, Current protein & peptide science.

[146]  M. Chorev.  The partial retro–inverso modification: A road traveled together , 2005, Biopolymers.

[147]  J. Wilschut,et al.  Virosomes for antigen and DNA delivery. , 2005, Advanced drug delivery reviews.

[148]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[149]  K. Berndt,et al.  Synthesis and biophysical characterization of engineered topographic immunogenic determinants with alpha alpha topology. , 1990, Biochemistry.

[150]  C. Morrison,et al.  HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  M. Grever,et al.  Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  D. Young,et al.  A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses1 , 2003, The Journal of Immunology.

[153]  J. Stroh,et al.  The Structural Basis for the Specificity of Epidermal Growth Factor and Heregulin Binding (*) , 1995, The Journal of Biological Chemistry.

[154]  Piero Musiani,et al.  Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice , 1998, The Journal of experimental medicine.

[155]  M. Spitz,et al.  Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. , 1999, Journal of the National Cancer Institute.

[156]  H. Pehamberger,et al.  A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study , 2010, Breast Cancer Research and Treatment.

[157]  E. Perez,et al.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[159]  A. Thor,et al.  Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells , 2007, International journal of cancer.

[160]  I. Bauerfeind,et al.  Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients , 2004, Clinical Cancer Research.

[161]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[162]  Christoph C Zielinski,et al.  Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition. , 2005, Molecular immunology.

[163]  H. Esumi,et al.  Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. , 2002, Molecular biology of the cell.

[164]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[165]  T. Tzai,et al.  Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. , 1997, Anticancer research.

[166]  S. Pierce,et al.  Design and immunological properties of topographic immunogenic determinants of a protein antigen (LDH-C4) as vaccines. , 1992, The Journal of biological chemistry.

[167]  David S Mendelson,et al.  Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  M. Tafaghodi,et al.  Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[169]  K. Mills,et al.  Manipulating the immune system: humoral versus cell-mediated immunity. , 2001, Advanced drug delivery reviews.

[170]  T. Yano,et al.  Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. , 2006, Oncology reports.

[171]  S. Ménard,et al.  Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination , 2001, Gene Therapy.

[172]  Corey Smith,et al.  A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[173]  Eric M. Liotta,et al.  Engineered Conformation-dependent VEGF Peptide Mimics Are Effective in Inhibiting VEGF Signaling Pathways , 2011, The Journal of Biological Chemistry.

[174]  J. Stenvang,et al.  Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant , 2009, Breast Cancer Research and Treatment.

[175]  G. Hortobagyi,et al.  Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer , 2006, Nature Clinical Practice Oncology.

[176]  F. Grasselli,et al.  Angiogenic activity of swine granulosa cells: effects of hypoxia and vascular endothelial growth factor Trap R1R2, a VEGF blocker. , 2005, Domestic animal endocrinology.

[177]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[178]  M. Moran,et al.  Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer , 2001, Molecular and Cellular Biology.

[179]  T. Kurabayashi,et al.  Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells. , 2004, Endocrinology.

[180]  Parham Khosravi Shahi,et al.  Tumoral Angiogenesis: Review of the Literature , 2008 .

[181]  M. Pollak,et al.  Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. , 2002, Medical science monitor : international medical journal of experimental and clinical research.

[182]  V. Stevens,et al.  “De Novo” Engineering of Peptide Immunogenic and Antigenic Determinants as Potential Vaccines , 1994 .

[183]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[184]  M. Spitz,et al.  Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck Cancer , 2004, Clinical Cancer Research.

[185]  V. Hruby,et al.  Conformational and topographical considerations in the design of biologically active peptides , 1993, Biopolymers.

[186]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[187]  J. Folkman,et al.  Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.

[188]  N. Ferrara.  Vascular endothelial growth factor as a target for anticancer therapy. , 2004, The oncologist.

[189]  J. Baselga,et al.  Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 , 2009, Nature Reviews Cancer.

[190]  M. Piechocki,et al.  Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-21 , 2001, The Journal of Immunology.

[191]  A. Ryan,et al.  ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity , 2005, British Journal of Cancer.

[192]  R. Cardiff,et al.  Angiogenic Acceleration of Neu Induced Mammary Tumor Progression and Metastasis , 2004, Cancer Research.

[193]  M. Sliwkowski,et al.  A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. , 2008, Cancer research.

[194]  David Zurakowski,et al.  A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.

[195]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[196]  P. Elizalde,et al.  Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells , 2001, Oncogene.

[197]  C. Partidos,et al.  Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans. , 1990, The Journal of general virology.

[198]  G. Pawelec,et al.  Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope , 2001, British Journal of Cancer.

[199]  R. Herbst,et al.  Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[200]  J. Murray,et al.  Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. , 1997, Anticancer research.

[201]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[202]  S. Morrison,et al.  Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. , 2003, Vaccine.

[203]  R. Bast,et al.  Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. , 1991 .

[204]  A. Berezov,et al.  HER2/Neu: mechanisms of dimerization/oligomerization , 2000, Oncogene.

[205]  Cynthia X Ma,et al.  Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies. , 2012, Future oncology.

[206]  H. Fujii,et al.  Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma , 2005, British Journal of Cancer.

[207]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[208]  C. Ward,et al.  Structure and function of the type 1 insulin-like growth factor receptor , 2000, Cellular and Molecular Life Sciences CMLS.

[209]  E. Mittendorf,et al.  Evaluation of the HER2/neu‐derived peptide GP2 for use in a peptide‐based breast cancer vaccine trial , 2006, Cancer.

[210]  H. Dvorak,et al.  Vascular permeability, vascular hyperpermeability and angiogenesis , 2008, Angiogenesis.

[211]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[212]  D. Hallahan,et al.  Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. , 2006, International journal of radiation oncology, biology, physics.

[213]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[214]  J. Gralow,et al.  Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. , 1996, Journal of immunology.

[215]  Edward S. Kim,et al.  Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. , 2006, Cancer research.

[216]  R. Sundaram,et al.  Synthetic peptides as cancer vaccines. , 2002, Biopolymers.

[217]  R. Lal,et al.  Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction , 1995, Journal of virology.

[218]  Birgit Schoeberl,et al.  An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. , 2010, Cancer research.

[219]  R. Sutherland.  Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4 , 2011, Breast Cancer Research.

[220]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.